{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:02:43Z","timestamp":1761919363559,"version":"build-2065373602"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.3816\/clml.2010.s.003","type":"journal-article","created":{"date-parts":[[2010,6,8]],"date-time":"2010-06-08T21:18:41Z","timestamp":1276031921000},"page":"S20-S26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"S1","title":["How Much and How Long: Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia"],"prefix":"10.3816","volume":"10","author":[{"given":"Elie","family":"Traer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael W.","family":"Deininger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CLML.2010.s.003_bib1","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1126\/science.7892601","article-title":"Tyrosine kinase inhibition: an approach to drug development","volume":"267","author":"Levitzki","year":"1995","journal-title":"Science"},{"key":"10.3816\/CLML.2010.s.003_bib2","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"key":"10.3816\/CLML.2010.s.003_bib3","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.3816\/CLML.2010.s.003_bib4","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/asheducation-2008.1.419","article-title":"Milestones and monitoring in patients with CML treated with imatinib","author":"Deininger","year":"2008","journal-title":"Hematology"},{"key":"10.3816\/CLML.2010.s.003_bib5","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.3816\/CLML.2010.s.003_bib6","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.003_bib7","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.3816\/CLML.2010.s.003_bib8","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N Engl J Med"},{"key":"10.3816\/CLML.2010.s.003_bib9","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"10.3816\/CLML.2010.s.003_bib10","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1182\/blood-2003-11-3800","article-title":"High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia","volume":"103","author":"Kantarjian","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.003_bib11","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1182\/blood-2008-06-161737","article-title":"Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg\/day of imatinib as initial therapy","volume":"112","author":"Hughes","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.003_bib12","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1182\/blood-2008-12-191254","article-title":"Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study","volume":"113","author":"Baccarani","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.003_bib13","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1182\/blood.V112.11.130.130","volume":"112","author":"Cortes","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.003_bib14","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","article-title":"Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study","volume":"99","author":"Sawyers","year":"2002","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.003_bib15","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","article-title":"Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study","volume":"99","author":"Talpaz","year":"2002","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.003_bib16","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2002-05-1451","article-title":"Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia","volume":"101","author":"Kantarjian","year":"2003","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.003_bib17","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/cncr.24066","article-title":"Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase","volume":"115","author":"Kantarjian","year":"2009","journal-title":"Cancer"},{"key":"10.3816\/CLML.2010.s.003_bib18","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"109","author":"Picard","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.003_bib19","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.003_bib20","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s12185-009-0263-z","article-title":"Long-term efficacy of imatinib in a practical setting is correlated with imatinib trough concentration that is influenced by body size: a report by the Nagasaki CML Study Group","volume":"89","author":"Sakai","year":"2009","journal-title":"Int J Hematol"},{"key":"10.3816\/CLML.2010.s.003_bib21","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1182\/blood-2005-03-1103","article-title":"In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML","volume":"106","author":"White","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.003_bib22","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2005-11-4687","article-title":"OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib","volume":"108","author":"White","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.003_bib23","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood-2007-06-093617","article-title":"Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity","volume":"110","author":"White","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.003_bib24","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1182\/blood-2005-02-0694","article-title":"hOCT 1 and resistance to imatinib","volume":"106","author":"Crossman","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.003_bib25","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/sj.clpt.6100268","article-title":"Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia","volume":"83","author":"Wang","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.3816\/CLML.2010.s.003_bib26","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/jnci\/91.2.163","article-title":"In vivo eradication of human BCR\/ABL-positive leukemia cells with an ABL kinase inhibitor","volume":"91","author":"le Coutre","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CLML.2010.s.003_bib27","doi-asserted-by":"crossref","first-page":"6414","DOI":"10.1158\/1078-0432.CCR-05-0790","article-title":"Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen","volume":"11","author":"Johnson","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLML.2010.s.003_bib28","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1158\/1078-0432.CCR-06-2328","article-title":"Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma","volume":"13","author":"Goodman","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLML.2010.s.003_bib29","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","article-title":"Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia","volume":"26","author":"Shah","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.s.003_bib30","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1182\/blood-2006-11-056028","article-title":"Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.003_bib31","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"key":"10.3816\/CLML.2010.s.003_bib32","doi-asserted-by":"crossref","first-page":"6322","DOI":"10.1182\/blood-2008-11-186817","article-title":"Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up","volume":"113","author":"Kantarjian","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.003_bib33","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ccr.2008.11.001","article-title":"Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis","volume":"14","author":"Shah","year":"2008","journal-title":"Cancer Cell"},{"key":"10.3816\/CLML.2010.s.003_bib34","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1182\/blood-2007-10-113969","article-title":"Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis","volume":"114","author":"Snead","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.003_bib35","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s00277-003-0644-y","article-title":"Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique [erratum published in: Ann Hematol 2003; 82:660]","volume":"82","author":"Kreuzer","year":"2003","journal-title":"Ann Hematol"},{"issue":"suppl 2","key":"10.3816\/CLML.2010.s.003_bib36","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1053\/shem.2003.50046","article-title":"Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment","volume":"40","author":"Roche-Lestienne","year":"2003","journal-title":"Semin Hematol"},{"key":"10.3816\/CLML.2010.s.003_bib37","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1182\/blood-2005-03-1036","article-title":"High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy","volume":"106","author":"Willis","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.003_bib38","doi-asserted-by":"crossref","first-page":"4933","DOI":"10.1182\/blood-2009-07-232595","article-title":"Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia","volume":"114","author":"Rosti","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.003_bib39","first-page":"143","article-title":"Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP)","volume":"114","author":"Cortes","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.003_bib40","doi-asserted-by":"crossref","unstructured":"Saglio S, Kim DW, Issaragrisil S, et al. Nilotinib demonstrates superior efficacy compared with imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase: results from the international randomized phase III ENESTnd trial. Paper presented at: the 51st Annual Meeting of the American Society of Hematology; December 5-8, 2009; New Orleans, LA. Abstract LBA-1.","DOI":"10.1182\/blood.V114.22.LBA-1.LBA-1"},{"key":"10.3816\/CLML.2010.s.003_bib41","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2007-07-103523","article-title":"Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment","volume":"111","author":"Hochhaus","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.003_bib42","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years","volume":"109","author":"Rousselot","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.003_bib43","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1182\/blood.V114.22.859.859","article-title":"Discontinuation of imatinib therapy after achieving a molecular response in chronic myeloid leukemia patients","volume":"114","author":"Mahon","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.003_bib44","first-page":"353","article-title":"Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation","volume":"114","author":"Holtz","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.003_bib45","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1182\/blood.V97.3.720","article-title":"Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3","volume":"97","author":"Holyoake","year":"2001","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.003_bib46","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/sj.leu.2404609","article-title":"Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies","volume":"21","author":"Jiang","year":"2007","journal-title":"Leukemia"},{"key":"10.3816\/CLML.2010.s.003_bib47","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","article-title":"Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction","volume":"107","author":"Copland","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.003_bib48","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1182\/blood-2006-11-057521","article-title":"Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells","volume":"109","author":"Jorgensen","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.003_bib49","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.ceb.2004.09.004","article-title":"Diverse mechanisms regulate stem cell self-renewal","volume":"16","author":"Molofsky","year":"2004","journal-title":"Curr Opin Cell Biol"},{"key":"10.3816\/CLML.2010.s.003_bib50","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ccr.2007.11.003","article-title":"Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo","volume":"12","author":"Zhao","year":"2007","journal-title":"Cancer Cell"},{"key":"10.3816\/CLML.2010.s.003_bib51","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ccr.2008.08.003","article-title":"Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation","volume":"14","author":"Dierks","year":"2008","journal-title":"Cancer Cell"},{"key":"10.3816\/CLML.2010.s.003_bib52","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nature07737","article-title":"Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia","volume":"458","author":"Zhao","year":"2009","journal-title":"Nature"},{"key":"10.3816\/CLML.2010.s.003_bib53","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1038\/sj.leu.2403785","article-title":"Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro","volume":"19","author":"Jorgensen","year":"2005","journal-title":"Leukemia"},{"key":"10.3816\/CLML.2010.s.003_bib54","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.1182\/blood-2009-05-219550","article-title":"BMS-214662 induces mitochondrial apoptosis in chronic myeloid leukemia (CML) stem\/progenitor cells, including CD34+38- cells, through activation of protein kinase Cbeta","volume":"114","author":"Pellicano","year":"2009","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011700556?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011700556?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:23:11Z","timestamp":1761870191000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265011700556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":54,"alternative-id":["S2152265011700556"],"URL":"https:\/\/doi.org\/10.3816\/clml.2010.s.003","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2010,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How Much and How Long: Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CLML.2010.s.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}